Cuiyan Guo

Cuiyan Guo

Auto-generated profile, based on publicly available information

Cuiyan Guo

Department of Respiratory and Critical Care Medicine Peking University First Hospital Beijing China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2022 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
Yan HuYan Hu
Yan Hu
QYQing Yu
Qing Yu
CGCuiyan Guo
Cuiyan Guo
GWGuangfa Wang
Guangfa Wang
Background DNA aneuploidy has a potential to become an adjunct to conventional cytology for diagnosis of lung cancer, but its value in bronchial washings has not been well evaluated. Methods We conducted a retrospective study on patients who underwent bronchoscopy and the bronchial washings were submitted for both cytology and DNA image cytometry (DNA-ICM) examination. The sensitivity and specificity of two methods and both in combination were compared. Analysis of clinical subgroups and DNA histogram were also performed. Results The study included 626 patients (326 patients with lung cancer and 300 patients with benign lung diseases). The sensitivity of cytology, DNA-ICM, and combination test for lung cancer were 53.3%, 62.3%, and 75.8%, respectively, and the sensitivity of DNA-ICM and combination test were superior to that of cytology (p < 0.05). A modest reduction of specificity was found in DNA-ICM compared with cytology (91.3% vs. 98.3%, p < 0.05). Subgroup analysis showed there was no significant difference in sensitivity of DNA-ICM between the visible tumor group and the invisible tumor group (66.5% vs. 56.9%, χ2 = 3.114, p = 0.078). Among 101 patients with invisible endobronchial tumor, the positive rates for DNA-ICM of washing, cytology of washing, brushing and biopsy were 62.4%, 41.6%, 40.6%, and 45.5%, respectively. DNA-ICM in combination with the basic bronchoscopy techniques could increase the sensitivity from 67.3% to 87.1% (p = 0.000). The DNA histogram analysis showed 25.3% washing samples of lung cancer were diploid pattern, 49.4% were scattered aneuploid cells pattern, and 25.3% were aneuploid peaks pattern. Small cell lung cancer had the highest proportion of aneuploid peaks pattern (p < 0.05). Conclusions DNA-ICM could be used as an adjunct for the detection of lung cancer. The combination of DNA-ICM and basic bronchoscopy techniques could significantly increase the sensitivity, especially for the patients suspected of peripheral lung cancer, and contribute to select subjects for advanced bronchoscopy.

19 August 2022 in Diagnostic Cytopathology
Verified
Journal Article
Open access
CGCuiyan Guo
Cuiyan Guo
YHYan Hu
Yan Hu
QYQing Yu
Qing Yu
QZQi Zhang
Qi Zhang
GWGuangfa Wang
Guangfa Wang
Objective: To explore the diagnostic value of DNA aneuploidy analysis combined with radial endobronchial ultrasound (R‐EBUS)‐guided transbronchial biopsy in peripheral lung lesions.Method: We performed a retrospective analysis of patients who underwent R‐EBUS examination. DNA aneuploidy analysis of bronchial washing from the target bronchial segment were performed. The clinical information, R‐EBUS data, pathological results and DNA image cytometry (DNA‐ICM) results were collected. For patients who did not have a clear diagnosis after bronchoscopy, follow‐up data was recorded.Results: A total of 42 cases were included. Thirty patients had confirmed malignant tumor of the lung, 19 of which were confirmed by pathology after bronchoscopy, and 11 cases were confirmed later by surgery or percutaneous lung puncture. Twelve patients were finally considered to have benign lesions. The sensitivity of R‐EBUS is 63.3% and the specificity is 100%. DNA‐ICM has a sensitivity of 76.7% and a specificity of 91.7%. When combined, they have a sensitivity of 90%, and specificity 91.7%. As for malignant lesions, we further analyzed smoking, the size and location of lesions on chest CT, the number of aneuploid cells and the maximum value of DNA content. The results indicated that increased number of aneuploid cells or increased max value of DNA content may predict higher probability of malignancy.Conclusion: DNA‐ICM combined with R‐EBUS can improve the diagnostic sensitivity of malignant peripheral lung lesions. Increased number of aneuploid cells or increased max value of DNA content may indicate that the lesions are more likely to be malignant.

9 May 2024 in Health Science Reports
Verified
Journal Article
Open access
XZXiang Zhao
Xiang Zhao
YCYuan Cheng
Yuan Cheng
CGCuiyan Guo
Cuiyan Guo
LNLigong Nie
Ligong Nie
QZQi Zhang
Qi Zhang
GWGuangfa Wang
Guangfa Wang
Background and Aims: Immune checkpoint inhibitors (ICIs) across multiple treatment lines have not yet been evaluated comprehensively. The purpose of this research was to investigate whether or not continuous cross‐line ICIs therapy is effective in treating non‐small cell lung cancer (NSCLC).Methods: We conducted a retrospective investigation into the medical histories of 47 patients diagnosed with advanced NSCLC and treated with ICIs at the Peking University First Hospital between January 2018 and June 2022.Results: Due to the progression of their disease, 14 patients were given the same ICIs, 5 patients were given different ICIs, and 6 patients discontinued taking ICIs altogether. The objective response rates were 7.140% in the ICIs cross‐line treatment group, 0% in the replacement of ICIs treatment group, and 0% in the discontinuation of ICIs treatment group. The disease control rates were 64.260% in the ICIs cross‐line treatment group, 60% in the replacement of ICIs treatment group, and 0% in the discontinuation of ICIs treatment group. The average overall survival durations of the three groups were 24.020 (95% confidence interval [CI]: 17.061–30.979), 31.643 (95% CI: 23.513–39.774), and 7.997 (95% CI: 3.746–12.247) months, respectively (p = 0.003). The median second progression‐free survival (PFS2) durations of the three groups were 4.570 (95% CI: 3.276–5.864), 3.530 (95% CI: 0.674–6.386), and 1.570 (95% CI: 0–4.091) months, respectively (p = 0.091).Conclusions: Cross‐line ICIs cannot improve the prognosis and PFS2 of patients with NSCLC, but compared to discontinuing ICIs, OS may be prolonged. A few patients may benefit from prolonged ICIs therapy.

11 December 2023 in The Clinical Respiratory Journal
Verified
Journal Article
Open access
CGCuiyan Guo
Cuiyan Guo
QZQi Zhang
Qi Zhang
YHYan Hu
Yan Hu
JHJunfang Huang
Junfang Huang
SWShixuan Wang
Shixuan Wang
GWGuangfa Wang
Guangfa Wang
Objective: The objective of this study is to study the adjunct role of combining DNA aneuploidy analysis with radial endobronchial ultrasound (R‐EBUS)‐guided sampling for diagnosis of peripheral lung lesions (PPLs). Method: A single‐center prospective study was conducted in patients undergoing R‐EBUS‐guided sampling for PPLs. DNA image cytometry (DNA‐ICM) was used to analyze DNA aneuploidy in bronchial washing from the bronchial segment of the PPL. Clinical information, R‐EBUS data, pathology, DNA‐ICM results, and follow‐up data were analyzed. Sensitivity, specificity, and predictive values for R‐EBUS‐guided sampling, DNA‐ICM, and the two methods combined were measured. Binary logistic regression was performed to determine influencing factors on diagnostic positivity rate. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cutoff point for DNA‐ICM. Results: A total of 101 patients were enrolled. Sixty‐four (63.4%) patients had confirmed malignant tumor, of whom 33 were confirmed by R‐EBUS‐guided sampling (biopsy and/or bronchial brush and wash cytology), and 31 by surgery or percutaneous lung biopsy. Thirty‐seven patients were finally considered to have benign lesions, based on clinical information and 1‐year follow‐up. The sensitivity for malignant disease was 51.6% by R‐EBUS, and specificity was 100%. DNA‐ICM had a sensitivity of 67.2% and a specificity of 86.5%. When combining the two methods, sensitivity increased to 78.1% and specificity was 86.5%. Lesion size and whether the R‐EBUS probe was located in the lesion were significantly associated with positivity rate of the combined methods. The optimal cutoff point for DNA‐ICM was 5c for max DNA content, and 1 for aneuploid cell count (sensitivity 67.2%, specificity 86.5%, accuracy 63.4%). Conclusion: In malignant PPLs, DNA‐ICM combined with R‐EBUS‐guided sampling can improve diagnostic positivity compared with either method alone.

4 November 2020 in Trials
Verified
Journal Article
Open access
PDF file
XYXiaoyu Yang
Xiaoyu Yang
JHJunjun Huang
Junjun Huang
Yan HuYan Hu
Yan Hu
CGCuiyan Guo
Cuiyan Guo
XWXi Wang
Xi Wang
GWGuangfa Wang
Guangfa Wang
Background: Asthma is a common chronic airway inflammatory disease. Exacerbations of asthma not only accelerate the progression of the disease but also increase the incidence of hospitalization and death. Studies have shown that air pollution is a high-risk factor for asthma exacerbations. However, few treatment strategies have been recommended to reduce the risk of severe air pollution-related asthma exacerbations. Methods/design: This is a single-centre, prospective, randomized and standard treatment parallel control clinical trial. Seventy-two asthma patients in the nonexacerbation stage according to GINA guidelines 2017 will be recruited and randomized into the rescue intervention strategy (RIS) group and control group. Original treatments for the participants will include no use of inhaled medicine, the use of short-acting β-agonists (SABA) on demand or the use of budesonide/formoterol (160 μg/4.5 μg/dose, 1–2 dose/time, b.i.d.). The rescue intervention strategy for the RIS group will be budesonide/formoterol plus the original treatment until the severe pollution ends (air quality index, AQI < 200). The control group will maintain the original treatment. The follow-up observation period will last 1 year. The primary outcome is the frequency of asthma exacerbations per year. Secondary outcomes include the mean number of unplanned outpatient visits, emergency visits, hospitalizations, medical costs and mortality caused by asthma exacerbations per patient per year. Discussion: The results of this trial will provide a novel strategy to guide clinical practice in decreasing the risk of asthma exacerbations under severe air pollution. Trial registration: ChiCTR ChiCTR1900026757. Registered on 20 October 2019—retrospectively registered